
Atriva Therapeutics gets €24m from EIB
According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

How stress brings cancer to life again
An international research team led by AstraZeneca’s oncology expert Dmitry I. Gabrilovich report that that stressed neutrophils might act as a...

Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...

EU COVID-19 antibody ready for clinical trials
CORAT Therapeutics reports the start of production of the first batch of the therapeutic human COVID-19 antibody COR-101 for Phase I testing....

Topas raises €22m in Series B financining
Topas Therapeutics GmbH has closed a €22m (~$26mn) Series B financing round co-led by Vesalius BioCapital III and BioMedPartners with participation...